Therapeutic Products: Integrity, Transparency and Discounts
12 April 2019 – As of 1 January 2020, new rules on integrity, transparency and discounts will apply in the field of therapeutic products. At its meeting of 10 April 2019, the Federal Council adopted a new Ordinance on Integrity and Transparency in the Context of Therapeutic Products (OITTP; Verordnung über die Integrität und Transparenz im Heilmittelbereich, VITH) based on the revised Therapeutic Products Act (TPA; Heilmittelgesetz, HMG). The prescription and supply of medicinal products shall not be influenced by financial incentives of any sort. In addition, price discounts and refunds for the purchase of therapeutic products must be reported and disclosed to the FOPH in the future (for further information, see: here).